Publications

Found 3 results
Filters: Author is F. Mahjoubi  [Clear All Filters]
2012
F. Izadi, Mahjoubi, F., Farhadi, M., Tavakoli, M. M., and Samanian, S., A novel missense mutation in exon 7 of the ECM1 gene in an Iranian lipoid proteinosis patient, vol. 11, pp. 3955-3960, 2012.
Bhalerao J, Tylzanowski P, Filie JD, Kozak CA, et al. (1995). Molecular cloning, characterization, and genetic mapping of the cDNA coding for a novel secretory protein of mouse. Demonstration of alternative splicing in skin and cartilage. J. Biol. Chem. 270: 16385-16394. PMid:7608209   Chan I, El-Zurghany A, Zendah B, Benghazil M, et al. (2003). Molecular basis of lipoid proteinosis in a Libyan family. Clin. Exp. Dermatol. 28: 545-548. http://dx.doi.org/10.1046/j.1365-2230.2003.01341.x PMid:12950350   Chan I, Sethuraman G, Sharma VK, Bruning E, et al. (2004). Molecular basis of lipoid proteinosis in two Indian siblings. J. Dermatol. 31: 764-766. PMid:15628326   Chan I, Liu L, Hamada T, Sethuraman G, et al. (2007). The molecular basis of lipoid proteinosis: mutations in extracellular matrix protein 1. Exp. Dermatol. 16: 881-890. http://dx.doi.org/10.1111/j.1600-0625.2007.00608.x PMid:17927570   Hamada T, McLean WH, Ramsay M, Ashton GH, et al. (2002). Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hum. Mol. Genet. 11: 833-840. http://dx.doi.org/10.1093/hmg/11.7.833 PMid:11929856   Hamada T, Wessagowit V, South AP, Ashton GH, et al. (2003). Extracellular matrix protein 1 gene (ECM1) mutations in lipoid proteinosis and genotype-phenotype correlation. J. Invest. Dermatol. 120: 345-350. http://dx.doi.org/10.1046/j.1523-1747.2003.12073.x PMid:12603844   Han Z, Ni J, Smits P, Underhill CB, et al. (2001). Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells. FASEB J. 15: 988-994. http://dx.doi.org/10.1096/fj.99-0934com PMid:11292659   Horev L, Potikha T, Ayalon S, Molho-Pessach V, et al. (2005). A novel splice-site mutation in ECM-1 gene in a consanguineous family with lipoid proteinosis. Exp. Dermatol. 14: 891-897. http://dx.doi.org/10.1111/j.1600-0625.2005.00374.x PMid:16274456   Mathieu E, Meheus L, Raymackers J and Merregaert J (1994). Characterization of the osteogenic stromal cell line MN7: identification of secreted MN7 proteins using two-dimensional polyacrylamide gel electrophoresis, western blotting, and microsequencing. J. Bone Miner. Res. 9: 903-913. http://dx.doi.org/10.1002/jbmr.5650090616 PMid:8079665   Muda AO, Paradisi M, Angelo C, Mostaccioli S, et al. (1995). Lipoid proteinosis: clinical, histologic, and ultrastructural investigations. Cutis 56: 220-224. PMid:8575221   Oz F, Kalekoglu N, Karakullukcu B, Ozturk O, et al. (2002). Lipoid proteinosis of the larynx. J. Laryngol. Otol. 116: 736-739. http://dx.doi.org/10.1258/002221502760238082 PMid:12437814   Smits P, Ni J, Feng P, Wauters J, et al. (1997). The human extracellular matrix gene 1 (ECM1): genomic structure, cDNA cloning, expression pattern, and chromosomal localization. Genomics 45: 487-495. http://dx.doi.org/10.1006/geno.1997.4918 PMid:9367673   Urbach E and Wiethe C (1929). Lipoidosis cutis et mucosae. Virchows Arch. Pathol. Anat. Physiol. 273: 285-319. http://dx.doi.org/10.1007/BF02158983   Van Hougenhouck-Tulleken W, Chan I, Hamada T, Thornton H, et al. (2004). Clinical and molecular characterization of lipoid proteinosis in Namaqualand, South Africa. Br. J. Dermatol. 151: 413-423. http://dx.doi.org/10.1111/j.1365-2133.2004.06076.x PMid:15327549   Wang CY, Zhang PZ, Zhang FR, Liu J, et al. (2006). New compound heterozygous mutations in a Chinese family with lipoid proteinosis. Br. J. Dermatol. 155: 470-472. http://dx.doi.org/10.1111/j.1365-2133.2006.07292.x PMid:16882193
2010
M. Taheri, Mahjoubi, F., and Omranipour, R., Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients, vol. 9, pp. 34-40, 2010.
Atalay C, Deliloglu GI, Irkkan C and Gunduz U (2006). Multidrug resistance in locally advanced breast cancer. Tumour Biol. 27: 309-318. http://dx.doi.org/10.1159/000096086 PMid:17033200   Chang H, Rha SY, Jeung HC, Im CK, et al. (2009). Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann. Oncol. 20: 272-277. http://dx.doi.org/10.1093/annonc/mdn624 PMid:18836089   Decleves X, Fajac A, Lehmann-Che J, Tardy M, et al. (2002). Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int. J. Cancer 98: 173-180. http://dx.doi.org/10.1002/ijc.10135 PMid:11857404   Golalipour M, Mahjoubi F, Sanati MH and Alimoghaddam K (2007). Gene dosage is not responsible for the upregulation of MRP1 gene expression in adult leukemia patients. Arch. Med. Res. 38: 297-304. http://dx.doi.org/10.1016/j.arcmed.2006.10.016 PMid:17350479   Gottesman MM, Fojo T and Bates SE (2002). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2: 48-58. http://dx.doi.org/10.1038/nrc706 PMid:11902585   Hoffmeyer S, Burk O, von Richter O, Arnold HP, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 97: 3473-3478. http://dx.doi.org/10.1073/pnas.97.7.3473 PMid:10716719 PMCid:16264   Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, et al. (2004). Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72: 314-321. http://dx.doi.org/10.1111/j.1600-0609.2004.00228.x PMid:15059065   Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, et al. (2007). A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. http://dx.doi.org/10.1126/science.1135308 PMid:17185560   Kurzawski M, Drozdzik M, Suchy J, Kurzawski G, et al. (2005). Polymorphism in the P-glycoprotein drug transporter MDR1 gene in colon cancer patients. Eur. J. Clin. Pharmacol. 61: 389-394. http://dx.doi.org/10.1007/s00228-005-0926-5 PMid:15912392   Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, et al. (1995). Prognostic relevance of P-glycoprotein expression in breast cancer. Ann. Oncol. 6: 679-685. PMid:8664189   Rodrigues FF, Santos RE, Melo MB, Silva MA, et al. (2008). Correlation of polymorphism C3435T of the MDR-1 gene and the response of primary chemotherapy in women with locally advanced breast cancer. Genet. Mol. Res. 7: 177-183. http://dx.doi.org/10.4238/vol7-1gmr400 PMid:18393221   Sakaeda T (2005). MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab. Pharmacokinet. 20: 391-414. http://dx.doi.org/10.2133/dmpk.20.391 PMid:16415525   Turgut S, Yaren A, Kursunluoglu R and Turgut G (2007). MDR1 C3435T polymorphism in patients with breast cancer. Arch. Med. Res. 38: 539-544. http://dx.doi.org/10.1016/j.arcmed.2007.02.005 PMid:17560460   Urayama KY, Wiencke JK, Buffler PL and Wiemels JL (2002). The role of MDR-1 gene polymorphisms in the genetic susceptibility to childhood leukemia. Ann. Epidemiol. 12: 497. http://dx.doi.org/10.1016/S1047-2797(02)00309-5   van der Deen M, de Vries EG, Timens W, Scheper RJ, et al. (2005). ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir. Res. 6: 59. http://dx.doi.org/10.1186/1465-9921-6-59 PMid:15967026 PMCid:1200430